open access
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase
inhibitors and bromodomain inhibitors to impede growth of lung
adenocarcinoma cells
.... We describe here the potential utility of Debio 1143 in combination with
taxanes, topoisomerase inhibitors, or bromodomain inhibitors. The
combination of Debio 1143 with both paclitaxel and carboplatin is in
clinical trials for lung squamous cell carcinoma, platinum-refractory
ovarian carcinoma, and triple negative breast cancer (NCT01930292)......
Reference: (ovarian cancer)
18. Thibault BG, L.; Broca, C; Barbier, M.; Zanna, C.; Vuagniaux, G.;
Delord, J-P.; Couderc, B. (2015). The IAP inhibitor Debio 1143 reverses
carboplatin resistance in ovarian cancer cells by inducing both
apoptosis and necroptosis. AACR Annual Meeting 2015.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.